The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led non-profit organization, comprised of 99% volunteers and represents 32,000 Waldenstrom’s patients worldwide! They want you to know with the IWMF, you are never alone and anyone can become a member. As the IWMF strives to support the lives of those living with this rare cancer, the organization offers critical services to achieve that end.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Waldenstrom Macroglobulinemia
IWMF Webinar Provides In-Depth Info on WM
In a recent webinar hosted by the International Waldenström’s Macroglobulinemia Foundation (IWMF) and held on July 22nd, 2020, Dr. Jeffery Matous from the Colorado Blood
Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US
Study Aims to Discover How COVID-19 is Affecting WM Patients
A new study is seeking to understand how the ongoing coronavirus/COVID-19 pandemic is impacting patients with a rare blood cancer called Waldenström’s macroglobulinemia (WM). The
Zanubrutinib Versus Ibrutinib: Which is Better for WM?
According to a story from crweworld.com, the biopharmaceutical company BeiGene, Ltd. recently released the results of a phase 3 clinical trial. The goal of this
The IWMF Adds New IVIG for WM Treatment Fact Sheet
According to an announcement from the International Waldenstrom’s Macroglobulinemia Foundation (IWMF), the organization has recently added a new fact sheet to their website. This fact
IWMF and PleXus Communications are Teaming up to Help Spread Waldenstrom’s Macroglobulinemia Awareness
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) has recently announced an exciting new partnership that will help facilitate spreading awareness about Waldenstrom’s macroglobulinemia (WM), a rare
